Search
Who are we?
Started in 1885 by Albert Boehringer, this independent family-owned company has grown into a top contributor in Human Pharma and Animal Health.
Boehringer Ingelheim collaborates with the Broad Institute
Boehringer Ingelheim and researchers at the Broad Institute of MIT and Harvard are collaborating to tackle the unmet needs of people living with mental health conditions.
2021 PRRS Research Award winners announced
The 2021 European PRRS Research Award winners announced
U.S. FDA grants priority review for spesolimab in GPP
U.S. FDA grants priority review for spesolimab in the treatment of patients with generalized pustular psoriasis
Partnership Boehringer Ingelheim Lifebit health data
Boehringer Ingelheim and Lifebit announce partnership to capture transformational value of health data
Kicking off 2024 with five new R&D partnerships
We are kicking off 2024 with five new R&D partnerships to further enable and accelerate the company’s commitment to transform the lives of patients world-wide.
BI Focuses COVID-19 Clinical Research on Alteplase
BI focuses its COVID-19 therapy research on the development of alteplase as a potential treatment for COVID-19 patients with severe breathing problems
Boehringer expands cancer research at Vienna site
Boehringer Ingelheim expands cancer research at its Vienna site
Blue internal teat sealant now in dairy mastitis portfolio
Boehringer Ingelheim adds blue internal teat sealant to its dairy mastitis portfolio
Jean-Michel Boers Appointed to PhRMA Board of Directors
Jean-Michel Boers Appointed to PhRMA Board of Directors
Boehringer Ingelheim announces 2018 BVDzero Case Awards
Boehringer Ingelheim announces 2018 BVDzero Case Awards Boehringer Ingelheim will provide a total prize of €15,000 for the top 10 clinical cases entered Applications can be submitted on www.bvdzero.com
New biomass power plant Ingelheim
Boehringer Ingelheim produces its own green energy
New spesolimab data show significant improvement in GPP flares
New spesolimab data show significant improvement in GPP flares
Rethinking mental health care
Outdated perceptions and practices fuelling mental health crisis, new Economist Impact study reveals
sustainably fighting rabies info hub
Did you know that every nine minutes, rabies takes a human life? Find out how we support the elimination of this deadly disease.
World Rabies Day: BI fights rabies misconceptions
Boehringer Ingelheim joins efforts to fight rabies under this year’s theme for World Rabies Day to raise awareness of the disease and its prevention.
Partnership to Develop Urea Cycle Disorders Therapy
Boehringer Ingelheim Partners with Thoeris to Investigate a Novel Approach to Treat Urea Cycle Disorders
LastMile increases access to veterinary care in Africa
Boehringer Ingelheim’s LastMile initiative reaches over 40,000 smallholder farmers in Sub-Saharan Africa increasing access to veterinary medicine
We are Global Top Employer 2024
Global Top Employer certification reflects our impactful people development with high scores in development and steering practices as well as benefits on employee wellbeing.
Largest European development center for biotechnology
Boehringer Ingelheim inaugurates largest European development center for biotechnology
Niha Agarwalla
My career challenge at Boehringer Ingelheim by Niha Agarwalla. Read it now!
Development Biotechnology sustainable cell culture
Boehringer Ingelheim refines its bioprocess technology operations in Animal Health with greater focus on environmental sustainability to reduce footprint
Sabine Reinig
For Sabine, who leads Boehringer Ingelheim’s global people strategy, continuous development is the essence of a successful career. Clear aspirations and openness to new opportunities are her key ingredients.
Our-position
Potential access to selected medications for appropriate patients with serious, life-threatening diseases unable to participate in a clinical trial